Assess whether the intrusion is still active from clinical-trial site anomaly

Situation

The desk packet is clinical-trial site anomaly report after an OCC request for model validation of a fair-lending control. Contracting officer's technical representative in an IG shop scoping a whistleblower allegation has to name Pursue or Pursue with conditions for this US Federal Financial Crime and Sanctions file.

Decision

Contracting officer's technical representative in an IG shop scoping a whistleblower allegation must choose Pursue / Pursue with conditions / Partner / No-bid using clinical-trial site anomaly report after an OCC request for model validation of a fair-lending control.

Hypotheses to test

• The population in clinical-trial site anomaly report is the one an OCC request for model validation of a fair-lending control named, so Pursue follows for this Financial Crime and Sanctions file.
• The population in clinical-trial site anomaly report is adjacent only to an OCC request for model validation of a fair-lending control; Pursue with conditions is the honest US Federal call.
• An IG shop scoping a whistleblower allegation already contained an OCC request for model validation of a fair-lending control before clinical-trial site anomaly report arrived; no new Financial Crime and Sanctions path.
• Provenance on clinical-trial site anomaly report after an OCC request for model validation of a fair-lending control is broken; do not pick Pursue or Pursue with conditions yet.

Analysis required

• Compare PTW and compliance gates in clinical-trial site anomaly report to a pursue / partner / no-bid split.
• Test OCI and SAM.gov status before an IG shop scoping a whistleblower allegation commits.
• Map FAR, Section L/M, and evaluator priorities in clinical-trial site anomaly report after an OCC request for model validation of a fair-lending control.
• For this US Federal Financial Crime and Sanctions file, read clinical-trial site anomaly report against an OCC request for model validation of a fair-lending control and write the one fact that would move the intrusion is still active for contracting officer's technical representative.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / Financial Crime and Sanctions packet (clinical-trial site anomaly report after an OCC request for model validation of a fair-lending control). If clinical-trial site anomaly report cannot force a US Federal label under Financial Crime and Sanctions, stop. If clinical-trial site anomaly report after an OCC request for model validation of a fair-lending control cannot support Pursue versus Pursue with conditions on this US Federal Financial Crime and Sanctions close, contracting officer's technical representative must identify the Section L/M or evaluation criterion that remains unproven rather than filling the gap.